- Current report filing (8-K)

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  May 27, 2011

 

TIENS BIOTECH GROUP (USA), INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware		001-32477		75-2926439
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification Number)

 

 

No. 6, Yuanquan Road, Wuqing New-Tech Industrial Park, Tianjin, China 301700

(Address of principal executive offices)

 

Registrant's telephone number, including area code: (86) 22-8213-7658

 

Not applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

 

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

 

 

 

 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

On May 27, 2011, Tiens Biotech Group (USA), Inc. (the “Company”) held its annual meeting of stockholders (“Annual Meeting”) to vote on the following matters:

 

1.  Election of Directors

 

All of the following five nominees were elected to the Company’s Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.

 

 

Nominee		For		Against		Abstain		Broker Non-Votes
Jinyuan Li		67,960,358		2,950		283,744		0
Yupeng Yan		67,963,112		196		283,744		0
Baolan Li		67,960,358		2,950		283,744		0
Socorro Quintero		67,963,262		46		283,744		0
Gilbert Raker		67,963,262		46		283,744		0

 

2.           Ratification of the Company’s Independent Auditors

 

Stockholders ratified the appointment of Crowe Horwath LLP (“Crowe”) as independent auditors to audit the financial statements of the Company for the 2011 fiscal year, in accordance with the voting results listed below.

 

 

For		Against		Abstain		Broker Non-Votes
68,239,931		6,735		746		0

 

 

 

2

---

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	TIENS BIOTECH GROUP (USA), INC.
Date:  June 3, 2011	By:	/s/ Jinyuan Li
		Name:   Jinyuan Li
		Title:     Chief Executive Officer